Ali joined NEA in 2007 and is currently a General Partner on the healthcare team. He specializes in investments in the biopharmaceutical and medical device sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.
- May 23, 2018
- September 25, 2014
- November 6, 2013
Companies
- All
- Featured
- Current
- Boards
- IPOs
- Acquisitions
- 858 Therapeutics
- Acadia Pharmaceuticals
- Acclarent
- Aciex
- Acrivon Therapeutics
- Adaptimmune
- Affimed N.V.
- Arcellx
- Ardelyx
- Black Diamond Therapeutics
- BridgePoint Medical
- Cardionomic
- ClarVista Medical
- CRISPR
- CVRx
- Escient Pharmaceuticals
- Genocea
- Hyperion Therapeutics
- InterMune
- Ivantis
- Korro
- Lumena
- Marker Therapeutics
- Minerva Surgical
- Mirna Therapeutics
- Monte Rosa Therapeutics
- Motus Therapeutics
- Moximed
- Nevro
- Nkarta Therapeutics
- Oculeve
- Oyster Point
- Ra Pharmaceuticals
- Rhythm Pharmaceuticals
- Rotation Medical
- Solace Therapeutics
- SpyGlass Pharma
- Stablix
- Tidal Therapeutics
- Transcept/ Paratek Pharmaceuticals
- Trillium Therapeutics
- Tune Therapeutics
- Vitae Pharmaceuticals